---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/40171923.md"
description: "Hong Kong stock biopharma followed two trends today: Innovent Biologics rose over 3.5%, with PD-1 innovative drugs having staged catalysts, performing relatively steadily among Hong Kong-listed innovative drug stocks; AliHealth edged up 0.2%, with medical e-commerce almost flat. On the other hand, Xuanzhu Biopharma fell over 6%, as its clinical-stage pipeline needs time to validate, and capital lacks patience; Summit Therapeutics also saw a significant drop, with clinical small-cap stocks carrying relatively high risks 😔"
datetime: "2026-04-24T11:03:21.000Z"
locales:
  - [en](https://longbridge.com/en/topics/40171923.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/40171923.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/40171923.md)
author: "[Dimoo](https://longbridge.com/en/profiles/26968366.md)"
---

# Hong Kong stock biopharma followed two trends toda…


### Related Stocks

- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)
- [01801.HK](https://longbridge.com/en/quote/01801.HK.md)
- [00241.HK](https://longbridge.com/en/quote/00241.HK.md)
- [02575.HK](https://longbridge.com/en/quote/02575.HK.md)